{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:01:47Z","timestamp":1790596907312,"version":"4.1.0"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Vaccination is one of the most successful developments in the history of medicine, having saved countless human lives. Although vaccination is of the utmost importance for patients with hematological neoplasms, it can also be challenging due to the often reduced or absent serological responses. Despite vaccination, breakthrough infections may occur among patients with hematological malignancies, particularly in those with impaired vaccine-induced immune responses. Although humoral responses are frequently impaired, vaccine-induced cellular immunity is preserved in a substantial proportion of patients with hematological malignancies and may contribute to protection against severe infections. Maximizing the immune response to vaccination requires optimal timing of vaccination relative to the administration of antineoplastic therapy. Patients may also fear vaccine side effects and worry that vaccination might influence their cancer therapy. Finally, some medical professionals, family members, and caregivers are insufficiently aware of the importance of vaccination for patients with hematological diseases, as well as their own vaccination. Despite significant developments in the field of vaccination of immunocompromised patients, addressing these challenges will require further high-quality clinical and translational research; continuous education of patients and healthcare providers; and enhanced cooperation and coordination among primary care practitioners, and epidemiological and hematological departments.<\/jats:p>","DOI":"10.3389\/fmed.2026.1911976","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:32:52Z","timestamp":1790595172000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Vaccination of patients with hematological malignancies: barriers and strategies to improve uptake"],"prefix":"10.3389","volume":"13","author":[{"given":"Toni","family":"Valkovi\u0107","sequence":"first","affiliation":[{"name":"Specialty Hospital Medico Rijeka","place":["Rijeka, Croatia"]},{"name":"Department for Medical Oncology and Hematology, Division for Internal Medicine, General Hospital Pula","place":["Pula, Croatia"]},{"name":"Faculty of Health Studies, Sveuciliste u Rijeci","place":["Rijeka, Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Salamon","sequence":"additional","affiliation":[{"name":"Specialty Hospital Medico Rijeka","place":["Rijeka, Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Vasiljev","sequence":"additional","affiliation":[{"name":"Department of Social Medicine and Epidemiology, Sveuciliste u Rijeci Medicinski Fakultet","place":["Rijeka, Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav","family":"Rukavina","sequence":"additional","affiliation":[{"name":"Department of Social Medicine and Epidemiology, Sveuciliste u Rijeci Medicinski Fakultet","place":["Rijeka, Croatia"]},{"name":"Teaching Institute of Public Health of Primorje-Gorski Kotar County","place":["Rijeka, Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"103896","DOI":"10.1016\/j.critrevonc.2022.103896","article-title":"Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology","volume":"181","author":"Shah","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e70850","DOI":"10.1002\/cam4.70850","article-title":"A population-based study of infectious diseases mortality risk in patients with hematologic malignancies 2000\u20132020","volume":"14","author":"Zheng","year":"2025","journal-title":"Cancer Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1086\/431521","article-title":"The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults","volume":"192","author":"Kyaw","year":"2005","journal-title":"J Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1648-2","article-title":"Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors","volume":"16","author":"Backhaus","year":"2016","journal-title":"BMC Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2014","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/cncr.21203","article-title":"Epidemiology and outcomes of serious influenza-related infections in the cancer population","volume":"104","author":"Cooksley","year":"2005","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1473-3099(09)70175-6","article-title":"Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses","volume":"9","author":"Kunisaki","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/2159-8290.CD-20-0516","article-title":"Case fatality rate of cancer patients with COVID-19 in a New York hospital system","volume":"10","author":"Mehta","year":"2020","journal-title":"Cancer Discov"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3109\/10428194.2011.584003","article-title":"The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies","volume":"52","author":"Monkman","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e2016044","DOI":"10.4084\/mjhid.2016.044","article-title":"Influenza and pneumococcal vaccination in hematological malignancies: a systematic review of efficacy, effectiveness and safety","volume":"8","author":"La Torre","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1054\/bjoc.1999.1088","article-title":"Immunogenicity of vaccination against influenza, streptococcus pneumoniae and haemophilus influenzae type B in patients with multiple myeloma","volume":"82","author":"Robertson","year":"2000","journal-title":"Br J Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.clml.2025.02.006","article-title":"Antibody response to pneumococcal, influenza, and COVID-19 vaccination in patients with multiple myeloma","volume":"25","author":"Singh","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B16","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/j.1600-0463.2012.02922.x","article-title":"Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma","volume":"120","author":"Hinge","year":"2012","journal-title":"APMIS"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/S0264-410X(00)00409-6","article-title":"Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia","volume":"19","author":"Hartkamp","year":"2001","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1365-2141.2001.02882.x","article-title":"Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia","volume":"114","author":"Sinisalo","year":"2001","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e114966","DOI":"10.1371\/journal.pone.0114966","article-title":"Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients \u2013 preliminary report","volume":"9","author":"Pasiarski","year":"2014","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.bbmt.2004.12.330","article-title":"Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation","volume":"11","author":"Antin","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm4065","article-title":"Polysaccharide and conjugate vaccines to streptococcus pneumoniae generate distinct humoral responses","volume":"14","author":"Davies","year":"2022","journal-title":"Sci Transl Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1600-0609.1989.tb01250.x","article-title":"Antibody response to pneumococcal vaccine in patients with early stage Hodgkin\u2019s disease","volume":"43","author":"Frederiksen","year":"1989","journal-title":"Eur J Haematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1128\/cdli.4.6.635-638.1997","article-title":"Antibody responses of splenectomized patients with non-Hodgkin\u2019s lymphoma to immunization with polyvalent pneumococcal vaccines","volume":"4","author":"Petrasch","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01321-w","article-title":"Humoral vaccine responses following chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"15","author":"Einarsdottir","year":"2025","journal-title":"Blood Cancer J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.3390\/cancers13236140","article-title":"Vaccine responses in adult hematopoietic stem cell transplant recipients: a comprehensive review","volume":"13","author":"Janssen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.3390\/biomedicines10112892","article-title":"Non-myelofibrosis chronic myeloproliferative neoplasm patients show better seroconversion rates after SARS-CoV-2 vaccination compared to other hematologic diseases: a multicentric prospective study of KroHem","volume":"10","author":"Serti\u0107","year":"2022","journal-title":"Biomedicines"},{"key":"B27","doi-asserted-by":"publisher","first-page":"109046","DOI":"10.1016\/j.intimp.2022.109046","article-title":"A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies","volume":"110","author":"Noori","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1093\/oncolo\/oyac032","article-title":"Impact of therapy in patients with hematologic malignancies on seroconversion rates after SARS-CoV-2 vaccination","volume":"27","author":"Guven","year":"2022","journal-title":"Oncologist"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00684-8","article-title":"Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review","volume":"12","author":"Piechotta","year":"2022","journal-title":"Blood Cancer J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1093\/infdis\/jiad174","article-title":"COVID-19 vaccination in patients with cancer and patients receiving HSCT or CAR-T therapy: immune response, real-world effectiveness, and implications for the future","volume":"228","author":"Hall","year":"2023","journal-title":"J Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s43018-022-00364-3","article-title":"Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study","volume":"3","author":"Lim","year":"2022","journal-title":"Nature Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1053\/j.seminhematol.2022.11.001","article-title":"SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies","volume":"59","author":"Haggenburg","year":"2022","journal-title":"Semin Hematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/2643-3230.BCD-22-0077","article-title":"Anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with hematologic malignancies","volume":"3","author":"Greenberger","year":"","journal-title":"Blood Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","first-page":"E457","DOI":"10.1002\/ajh.26729","article-title":"Increased CD8T-cell immunity after COVID-19 vaccination in lymphoid malignancy patients lacking adequate humoral response: an immune compensation mechanism?","volume":"97","author":"Boerenkamp","year":"2022","journal-title":"Am J Hematol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/bloodadvances.2021006101","article-title":"Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"6","author":"Jim\u00e9nez","year":"2022","journal-title":"Blood Adv. United States"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3390\/v15071439","article-title":"Comparative assessment of the kinetics of cellular and humoral immune responses to COVID-19 vaccination in cancer patients","volume":"15","author":"Souan","year":"2023","journal-title":"Viruses. Switzerland"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ccell.2022.03.013","article-title":"Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients","volume":"40","author":"Aleman","year":"2022","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/s43018-021-00275-9","article-title":"Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nat Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41577-024-01030-8","article-title":"Opportunities and challenges for T cell-based influenza vaccines","volume":"24","author":"Mosmann","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2395679","DOI":"10.1080\/21645515.2024.2395679","article-title":"The contributions of T cell-mediated immunity to protection from vaccine-preventable diseases: a primer","volume":"20","author":"Shapiro","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1182\/blood.2022017257","article-title":"Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey","volume":"140","author":"Pagano","year":"2022","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1182\/blood.2021013768","article-title":"Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting","volume":"139","author":"Mittelman","year":"2022","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"100931","DOI":"10.1016\/j.blre.2022.100931","article-title":"COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: a clarion call for maintaining mitigation and ramping-up research","volume":"54","author":"Wang","year":"2022","journal-title":"Blood Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01275-7","article-title":"SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders","volume":"15","author":"Pi\u00f1ana","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00778-3","article-title":"One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients","volume":"13","author":"Pi\u00f1ana","year":"2023","journal-title":"Blood Cancer J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"101077","DOI":"10.1016\/j.blre.2023.101077","article-title":"Vaccinations in hematological patients in the era of target therapies: lesson learnt from SARS-CoV-2","volume":"60","author":"Fattizzo","year":"2023","journal-title":"Blood Rev"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.3390\/jcm12175647","article-title":"Serological responses and predictive factors of booster COVID-19 vaccines in patients with hematologic malignancies","volume":"12","author":"Huang","year":"2023","journal-title":"J Clin Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ccell.2021.11.006","article-title":"Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer","volume":"40","author":"Shapiro","year":"2022","journal-title":"Cancer Cell"},{"key":"B50","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/bjh.18073","article-title":"Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres","volume":"197","author":"\u0160u\u0161ol","year":"2022","journal-title":"Br J Haematol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s43018-022-00369-y","article-title":"Impaired immune responses in blood cancers improved by third COVID-19 vaccine dose","volume":"3","author":"Lim","year":"2022","journal-title":"Nat Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006505.pub2","article-title":"Vaccines for prophylaxis of viral infections in patients with hematological malignancies","author":"Cheuk","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijid.2023.10.013","article-title":"Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: ePICOVIDEHA findings","volume":"137","author":"Rossi","year":"2023","journal-title":"Int J Infect Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s10238-023-01027-y","article-title":"Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study","volume":"23","author":"Oliva","year":"2023","journal-title":"Clin Exp Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"102318","DOI":"10.1016\/j.canep.2022.102318","article-title":"Vaccination against SARS-CoV-2 and risk of hospital admission and death among infected cancer patients: a population-based study in northern Italy","volume":"82","author":"Gobbato","year":"2023","journal-title":"Cancer Epidemiol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1182\/blood.2021014124","article-title":"COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA","volume":"139","author":"Pagano","year":"2021","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1097\/HS9.0000000000000789","article-title":"Improved clinical outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine: an EPICOVIDEHA report","volume":"6","author":"Salmanton-Garc\u00eda","year":"2022","journal-title":"HemaSphere"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26626","article-title":"Outcome of infection with omicron SARS-CoV -2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report","volume":"97","author":"Blennow","year":"2022","journal-title":"Am J Hematol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of adults with cancer: aSCO guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1516523","article-title":"Chrono-optimizing vaccine administration: a systematic review and meta-analysis","volume":"13","author":"Vink","year":"2025","journal-title":"Front Public Health"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e29116","DOI":"10.1016\/j.heliyon.2024.e29116","article-title":"Study of the cellular and humoral immune responses to SARS-CoV-2 vaccination","volume":"10","author":"Montmaneix-Engels","year":"2024","journal-title":"Heliyon. England"},{"key":"B62","doi-asserted-by":"publisher","first-page":"859019","DOI":"10.3389\/fimmu.2022.859019","article-title":"Humoral and cellular responses to BNT162b2 as a booster following two doses of ChAdOx1 nCov-19 determined using three SARS-CoV-2 antibody assays and an interferon-gamma release assay: a prospective longitudinal study in healthcare workers","volume":"13","author":"Jeong","year":"2022","journal-title":"Front Immunol. Switzerland"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1056\/NEJMc2113497","article-title":"COVID-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Jung","year":"2021","journal-title":"N Engl J Med. United States"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1370\/afm.20.s1.2638","article-title":"COVID-19 vaccination hesitancy among southern rural veterans with cancer in the Arkansas-Louisiana-Texas (ArkLATX) region","volume":"20","author":"Haddad","year":"2022","journal-title":"Ann Fam Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2334475","article-title":"Nonstructural barriers to adult vaccination","volume":"20","author":"Doherty","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B66","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3390\/vaccines11010180","article-title":"Understanding the barriers and attitudes toward influenza vaccine uptake in the adult general population: a rapid review","volume":"11","author":"Welch","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.amepre.2022.06.016","article-title":"Geographic heterogeneity in behavioral and social drivers of COVID-19 vaccination","volume":"63","author":"Masters","year":"2022","journal-title":"Am J Prev Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2127290","article-title":"Drivers of and barriers to routine adult vaccination: a systematic literature review","volume":"18","author":"Eiden","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12877-022-03653-9","article-title":"Increasing pneumococcal vaccine uptake in older adults: a scoping review of interventions in high-income countries","volume":"23","author":"Kirubarajan","year":"2023","journal-title":"BMC Geriatr"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International myeloma working group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","article-title":"Prevention and treatment of cancer-related infections, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Baden","year":"2024","journal-title":"J Natl Compr Cancer Network"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European conference on infections in leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B73","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/vaccines9050411","article-title":"Attitudes of patients with cancer towards vaccinations\u2014results of online survey with special focus on the vaccination against COVID-19","volume":"9","author":"Brodziak","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/vaccines9070792","article-title":"Acceptance of COVID-19 vaccination in cancer patients in Hong Kong: approaches to improve the vaccination rate","volume":"9","author":"Chan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"S1144","DOI":"10.1016\/j.annonc.2021.08.1588","article-title":"1595P Acceptance of COVID-19 vaccination among cancer patients in an Irish cancer centre","volume":"32","author":"Mullally","year":"2021","journal-title":"Ann Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e29872","DOI":"10.2196\/29872","article-title":"COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, and other serious comorbid conditions: a cross-sectional internet-based survey","volume":"8","author":"Tsai","year":"2021","journal-title":"JMIR Public Health Surveill"},{"key":"B77","doi-asserted-by":"publisher","first-page":"107680","DOI":"10.1016\/j.pec.2023.107680","article-title":"Vaccine hesitancy in cancer patients: a rapid review","volume":"111","author":"Butow","year":"2023","journal-title":"Patient Educ Couns"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.3390\/cancers13153883","article-title":"Cancer patients\u2019 willingness to take COVID-19 vaccination: a nationwide multicenter survey in Korea","volume":"13","author":"Chun","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B79","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ejca.2021.05.006","article-title":"The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: early data from a single-institute survey","volume":"153","author":"Di Noia","year":"2021","journal-title":"Eur J Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"ckab165.056","DOI":"10.1093\/eurpub\/ckab165.056","article-title":"COVID-19 vaccine hesitancy among Tunisian cancer patients in the Salah Azaeiz Institute of Cancer","volume":"31","author":"Cherif","year":"2021","journal-title":"Eur J Public Health"},{"key":"B81","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.annonc.2021.10.004","article-title":"SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment","volume":"33","author":"Figueiredo","year":"2022","journal-title":"Ann Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/tid.70113","article-title":"Respiratory syncytial virus exceeded SARS-CoV-2 and influenza in lower respiratory infection and mortality rates among patients with hematologic malignancies during the 2023\u20132024 respiratory virus season","volume":"27","author":"Shafat","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"i123","DOI":"10.1093\/cid\/ciag117","article-title":"IDSA 2025 guidelines on the use of vaccines for the prevention of seasonal RSV infections in immunocompromised patients","volume":"82","author":"Tan","year":"2026","journal-title":"Clin Infect Dis"},{"key":"B85","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases \u2014 advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat Rev Drug Discovery"},{"key":"B86","doi-asserted-by":"publisher","first-page":"ofac206","DOI":"10.1093\/ofid\/ofac206","article-title":"Safety and immunogenicity of an mRNA-based human metapneumovirus and parainfluenza virus type 3 combined vaccine in healthy adults","volume":"9","author":"August","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B87","doi-asserted-by":"publisher","first-page":"ofaf160","DOI":"10.1093\/ofid\/ofaf160","article-title":"A randomized phase 1 clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60\u201375 years of age","volume":"12","author":"Shapiro","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e0014626","DOI":"10.1128\/jvi.00146-26","article-title":"Combating respiratory diseases with mucosal vaccines","volume":"100","author":"Tang","year":"2026","journal-title":"J Virol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"116","DOI":"10.7774\/cevr.2025.14.e12","article-title":"Minireview: designing next generation human metapneumovirus (HMPV) vaccine","volume":"14","author":"Saeed","year":"2025","journal-title":"Clin Exp Vaccine Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"189577","DOI":"10.1016\/j.bbcan.2026.189577","article-title":"mRNA-based cancer vaccines: a new frontier in personalized immunotherapy","volume":"1881","author":"Garg","year":"2026","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/vaccines14030250","article-title":"Vaccination in oncology patients: evidence, clinical challenges, and future directions","volume":"14","author":"Agostara","year":"2026","journal-title":"Vaccines (Basel)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooag045","article-title":"Digital vaccines for immunization equity: an approach to strengthen vaccine delivery and public trust in low- and middle-income countries","volume":"9","author":"Othman","year":"2026","journal-title":"JAMIA Open"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1055\/s-0041-1739516","article-title":"Effect of electronic health record reminders for routine immunizations and immunizations needed for chronic medical conditions","volume":"12","author":"Stephens","year":"2021","journal-title":"Appl Clin Inform"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1097\/pq9.0000000000000532","article-title":"Urgent COVID-19 vaccination of healthcare workers via a quality improvement initiative","volume":"6","author":"Baumer-Mouradian","year":"2021","journal-title":"Pediatr Qual Saf"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1911976\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:32:53Z","timestamp":1790595173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1911976\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":94,"alternative-id":["10.3389\/fmed.2026.1911976"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1911976","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1911976"}}